Neuropsychiatric safety of varenicline in the general and COPD population with and without psychiatric disorders: a retrospective cohort study in a real-world setting

Study (n=6450) found similar rates of neuropsychiatric adverse events for varenicline vs nicotine replacement therapy in non-psychiatric (10.5% vs 12.6%) and psychiatric (75.3% vs 78.5%) cohorts. There were also no significant differences adverse event rates in those with COPD

Source:

BMJ Open